Multiplex Elisa For Huma Cytokine Panels

Description: ELISA kit for the detection of sVE Cadherin in the research laboratory

Description: A competitive ELISA for quantitative measurement of Canine True insulin in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Description: A competitive ELISA for quantitative measurement of Canine True insulin in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Description: A competitive ELISA for quantitative measurement of Canine True insulin in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Description: A competitive ELISA for quantitative measurement of Rabbit True insulin in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Description: A competitive ELISA for quantitative measurement of Rabbit True insulin in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Description: A competitive ELISA for quantitative measurement of Rabbit True insulin in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Description: A competitive ELISA for quantitative measurement of Mouse True insulin in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Description: Since December 2019, the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated disease, COVID-19, has caused a devastating pandemic worldwide.As the virus spreads globally, the continuous emergence of new mutant strains escalated the challenge on humans.To facilitate the mutant-related research, drug trials and vaccine development, a multiplex serological test for assessing antibody responses to mutant strains is in urgent need.

Description: Since December 2019, the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated disease, COVID-19, has caused a devastating pandemic worldwide.As the virus spreads globally, the continuous emergence of new mutant strains escalated the challenge on humans.To facilitate the mutant-related research, drug trials and vaccine development, a multiplex serological test for assessing antibody responses to mutant strains is in urgent need.

Description: Since December 2019, the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated disease, COVID-19, has caused a devastating pandemic worldwide. Omicron is a variant of SARS-CoV-2 first detected in November 2021 and is causing the ongoing COVID-19 pandemic. The Omicron subvariants BA.1 and BA.2 of SARS-CoV-2 have dominated the COVID-19 pandemic in early 2022. Its recent descendants BA.2.12.1 and BA.4/5 have surged dramatically to become dominant in the United States and South Africa, respectively. BA.2.12.1 and BA.4/BA.5 exhibit comparable ACE2-binding affinities to BA.2. Importantly, BA.2.12.1 and BA.4/BA.5 display stronger neutralization evasion than BA.2 against the plasma from 3-dose vaccination and, most strikingly, from post-vaccination BA.1 infections.Omicron BA.2.75 (a sub-variant of the BA.2 lineage) appears more transmissible than BA.5 in India and Nepal. Moreover, the World Health Organization (WHO) has lately classified BA.2.75 as a variant of concern lineages under monitoring (VOC-LUM).

Description: Since December 2019, the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated disease, COVID-19, has caused a devastating pandemic worldwide.As the virus spreads globally, the continuous emergence of new mutant strains escalated the challenge on humans.To facilitate the mutant-related research, drug trials and vaccine development, a high-throughput assay to measure IgG antibodies against the mutants is in urgent need.

Description: Since December 2019, the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated disease, COVID-19, has caused a devastating pandemic worldwide.As the virus spreads globally, the continuous emergence of new mutant strains escalated the challenge on humans.To facilitate the mutant-related research, drug trials and vaccine development, a multiplex serological test for assessing antibody responses to mutant strains is in urgent need.

Description: Since December 2019, the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated disease, COVID-19, has caused a devastating pandemic worldwide.As the virus spreads globally, the continuous emergence of new mutant strains escalated the challenge on humans.To facilitate the mutant-related research, drug trials and vaccine development, a multiplex serological test for assessing antibody responses to mutant strains is in urgent need.

Description: Since December 2019, the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated disease, COVID-19, has caused a devastating pandemic worldwide. Omicron is a variant of SARS-CoV-2 first detected in November 2021 and is causing the ongoing COVID-19 pandemic. The Omicron subvariants BA.1 and BA.2 of SARS-CoV-2 have dominated the COVID-19 pandemic in early 2022. Its recent descendants BA.2.12.1 and BA.4/5 have surged dramatically to become dominant in the United States and South Africa, respectively. BA.2.12.1 and BA.4/BA.5 exhibit comparable ACE2-binding affinities to BA.2. Importantly, BA.2.12.1 and BA.4/BA.5 display stronger neutralization evasion than BA.2 against the plasma from 3-dose vaccination and, most strikingly, from post-vaccination BA.1 infections.

Description: Since December 2019, the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated disease, COVID-19, has caused a devastating pandemic worldwide.As the virus spreads globally, the continuous emergence of new mutant strains escalated the challenge on humans.To facilitate the mutant-related research, drug trials and vaccine development, a high-throughput assay to measure IgG antibodies against the mutants is in urgent need.

Description: Since December 2019, the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated disease, COVID-19, has caused a devastating pandemic worldwide. Omicron is a variant of SARS-CoV-2 first detected in November 2021 and is causing the ongoing COVID-19 pandemic. The Omicron subvariants BA.1 and BA.2 of SARS-CoV-2 have dominated the COVID-19 pandemic in early 2022. Its recent descendants BA.2.12.1 and BA.4/5 have surged dramatically to become dominant in the United States and South Africa, respectively. BA.2.12.1 and BA.4/BA.5 exhibit comparable ACE2-binding affinities to BA.2. Importantly, BA.2.12.1 and BA.4/BA.5 display stronger neutralization evasion than BA.2 against the plasma from 3-dose vaccination and, most strikingly, from post-vaccination BA.1 infections.